Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

Key Points

• Xenon Pharmaceuticals reported a quarterly loss of $1.11 per share, beating analysts’ estimate of a $1.16 loss, though results were weaker than the $1.07 loss recorded in the same quarter last year.
• Management raised its 2026 revenue outlook to $610 million–$630 million, supported by stronger-than-expected Atera demand and resilient consumables growth. However, instrument revenue declined 47% year over year as customers delayed purchases ahead of the launch, with a modest Q3 decline expected before a Q4 recovery.
• Shares rose 0.4% to $64.55, while analysts maintained an overall “Buy” rating with an average price target of $77.20; institutional investors own approximately 95.45% of the stock.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05, FiscalAI reports. During the same quarter last year, the business posted ($1.07) EPS.

Here are the key takeaways from Xenon Pharmaceuticals' conference call:

• Atera demand significantly exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management said demand—not customer interest—is the constraint, with manufacturing capacity limiting near-term shipments.
• 10x raised its 2026 revenue outlook to $610 million–$630 million, implying 2%–5% underlying growth excluding settlement revenue. Second-quarter revenue was $151 million, or $149.4 million excluding the $1.6 million Takara settlement, while gross margin improved to 74%.
• Total instrument revenue fell 47% year over year, as customers delayed Xenium and Visium purchases ahead of Atera’s launch. Management expects a modest sequential revenue decline in Q3 from continued spatial transition effects before a significant Q4 increase as Atera shipments ramp.
• Core consumables remained resilient, with total consumables revenue up 7%, spatial consumables up 16%, and single-cell reaction volumes growing at a double-digit rate driven by Flex Apex. Management also characterized AI-driven demand for high-quality single-cell and spatial data as a significant long-term structural tailwind.
• Academic funding conditions remain tenuous; grant sentiment is improving, but funding has not yet translated consistently into purchasing because of allocation delays, oversight, and order-processing bottlenecks. The company’s guidance assumes the current macro environment persists rather than any meaningful academic-market recovery.

Xenon Pharmaceuticals Stock Up 0.4%

Shares of XENE traded up $0.25 during mid-day trading on Thursday, reaching $64.55. The company had a trading volume of 435,008 shares, compared to its average volume of 912,216. Xenon Pharmaceuticals has a 52-week low of $32.78 and a 52-week high of $72.66. The stock has a market capitalization of $6.24 billion, a P/E ratio of -13.73 and a beta of 0.62. The stock has a 50 day moving average of $60.06 and a two-hundred day moving average of $54.14.

Insider Activity

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the company's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gillian Cannon sold 1,190 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth approximately $33,000. Osaic Holdings Inc. boosted its position in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 1,034 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $43,000. Finally, State of Wyoming grew its holdings in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 350 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XENE. Needham & Company LLC cut their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Friday, May 8th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. JPMorgan Chase & Co. increased their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a report on Wednesday, May 27th. Finally, Wall Street Zen raised shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source